CompoAtlas

Mahisha Dravakam

Food supplement declared in France, declaration No 2023-9-438, decision dated 8 September 2023

Mahisha Dravakam is a food supplement declared in France. Status: declared in France, may be marketed. 2 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
Anjali d'Oc
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Bottle
Daily dose
25mL
Directions for use
Jusqu'à 5 cuillères à café par jour
Not recommended (according to the manufacturer)
Breastfeeding women, Pregnant women

Declaration 134632, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Cedrus libani A. Rich.BoisPoudre (de plantes séchées ou broyées)200 mg
Cyperus rotundus L.TuberculePoudre (de plantes séchées ou broyées)200 mg
Justicia adhatoda L.RacinePoudre (de plantes séchées ou broyées)200 mg
Tinospora sinensis (Lour.) Merr.TigePoudre (de plantes séchées ou broyées)200 mg
Withania somnifera (L.) DunalRacinePoudre (de plantes séchées ou broyées)200 mg
Zingiber officinale RoscoeRhizomePoudre (de plantes séchées ou broyées)200 mg

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Withania somnifera (L.) Dunal
    Read the warning, when it applies and the studies cited

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Sources cited by Health Canada (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Health Canada monograph dated 28 February 2025

  • Zingiber officinale Roscoe
    Read the warning, when it applies and the studies cited

    GINGER - ZINGIBER OFFICINALE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2023. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line